Kazia Therapeutics
KZIANASDAQStock · Data from SEC EDGAR 13F · Held by 1 of 87 tracked investors
Kazia Therapeutics at a glance
An overview of the financial statements, in plain language. Switch to the advanced view for charts.
- Valuation15
- Growth95
- Profitability15
- Quality20
- Debt100
- Stability8
- ✓It has more cash than debt.
- ✓The analysts' average target is 263% above the price.
- !The company is loss-making: net profit is negative.
- !In some year revenue fell sharply.
The score describes the quality and the past of the company based on its statements (the FinBoss model, indicative). A high score is not a buy signal and a low one is not a sell signal. Data source: Yahoo Finance, prices and statements in AUD.
Is the stock expensive?
ExpensiveThe company has no earnings, so the P/E cannot be calculated.
- P/E
- –
- P/S
- 49.2×
- EV/EBITDA
- -1.1×
Is the company growing?
–Too few years to compare. Last year 312.4%.
Does it make money?
Loss-makingNet margin: 0.0%.
Is it financially healthy?
Yes- Cash
Chart KZIA
Insider purchases
last 90 days, SEC Form 4Which investors hold this stock
1LC Leon Cooperman Cooperman (Omega Family Office) | 0.02% |
Frequently asked questions
How much is Kazia Therapeutics (KZIA) stock?
Kazia Therapeutics shares trade at $8.17, +3.81% over the last trading day. The price is delayed.
What is the market cap of Kazia Therapeutics?
The market cap of Kazia Therapeutics is about $93.4M.
Which big investors hold Kazia Therapeutics?
According to the latest 13F filings, 1 of 87 tracked investors hold Kazia Therapeutics, for example Leon Cooperman.
Source: SEC EDGAR 13F-HR (quarterly filings). The data is indicative and is not investment advice.